Eventide Asset Management

Boston, Massachusetts, United StatesFounded 2008

Eventide Asset Management is a Boston-based, values-based registered investment adviser founded in 2008 and inspired by a biblical worldview. It manages mutual funds, ETFs, and private funds—including the Eventide Healthcare Innovation Fund I, LP—focused on healthcare, life sciences, and technology, pursuing what it calls 'investing that makes the world rejoice.'

45% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 4 prior). Average disclosed round size is $110.7M (across 58 rounds with reported amounts).

Find people at Eventide Asset Management on Goldilocks AI

Portfolio

Fund Size

$83M

Top Stage

Series B

Last 12 Mo

Team

Finny Kuruvilla, MD, PhD

Co-Chief Investment Officer, Senior Portfolio Manager, Managing Director, Founding Member

I-hung Shih, PhD

Portfolio Manager, Managing Director

Carly Shotmeyer

Director of Strategic Planning & Communication for the CEO

Dolores Bamford, CFA

Co-Chief Investment Officer, Senior Portfolio Manager

Robin John

Chief Executive Officer, Founding Member

Colin Delaney

Head of Trading, Portfolio Specialist

Jennifer Reiche, IACCP®

Chief Compliance Officer

Kristin Kilmain

Head of Human Resources

Michael Schnackenberg

Head of Distribution

Peter Luiso

General Counsel

Sean Mathew, CPA

Chief Financial Officer

Tyler Frugia

Portfolio Manager, Head of Portfolio Analytics

Portfolio Breakdown

Stage Distribution

Sector Distribution

Investment Activity

DealsAvg Round Size

Portfolio

65 investments

Company	Round	Amount	Valuation	Date	Role
Flare Therapeutics	Series C	—	—	Jun 2026
Serapha Bio	Series A	$138M	—	Jan 2026
Entasis	Series B	$50M	—	Jan 2026
BBridgeBio Oncology Therapeutics	Unknown	$261M	—	Aug 2025
Avalyn Pharma, Inc.	Series D	$100M	—	Jul 2025
PreciseDx	Unknown	$11M	—	Jun 2025	lead
Kardium	Unknown	$250M	—	Jan 2025
BBridgeBio Oncology Therapeutics	Unknown	$260M	—	Jan 2025
Ovid Therapeutics Inc.	Series A	—	—	Jan 2025
Inventiva	Unknown	—	—	Oct 2024	participant
PreciseDx	Series B	$20.7M	—	Aug 2024	lead
PPreciseDx	Series B	$20.7M	—	Aug 2024
Freenome	Growth	$254M	—	Feb 2024
Sudo Biosciences	Series B	$147M	—	Jan 2024
Sudo	Series B	$147M	—	Jan 2024
Kestra Medical Technologies	Unknown	$196M	—	Jan 2024
Avalyn Pharma, Inc.	Series C	$175M	—	Sep 2023	co-lead
AAvalyn	Series C	$100M	—	Sep 2023
Beta Bionics	Series A	—	—	Sep 2023
Flare Therapeutics	Series B	$123M	—	Mar 2023	participant
Zentalis	Series C	$85M	—	Jan 2023
Avalyn Pharma, Inc.	Series C	$175M	—	Jan 2023
Beta Bionics	Series C	$57M	—	Feb 2022	co-lead
Freenome	Series D	$300M	—	Dec 2021	participant
Shoreline Biosciences	Series D	$140M	—	Nov 2021	participant